Compare BBSI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | CRMD |
|---|---|---|
| Founded | 1965 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.2M | 695.9M |
| IPO Year | 1994 | 2009 |
| Metric | BBSI | CRMD |
|---|---|---|
| Price | $37.42 | $8.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $42.67 | $14.83 |
| AVG Volume (30 Days) | 235.8K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | 5.05 | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $920,432,000.00 | $311,709,000.00 |
| Revenue This Year | $6.59 | $0.30 |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | ★ N/A | $20.63 |
| Revenue Growth | 9.50 | ★ 617.03 |
| 52 Week Low | $25.33 | $6.13 |
| 52 Week High | $49.65 | $14.96 |
| Indicator | BBSI | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 59.29 |
| Support Level | $35.95 | $8.09 |
| Resistance Level | $37.80 | $9.03 |
| Average True Range (ATR) | 1.29 | 0.39 |
| MACD | 0.28 | 0.04 |
| Stochastic Oscillator | 82.34 | 86.58 |
Barrett Business Services Inc is a provider of business management solutions for small and mid-sized companies through a platform that combines management consulting expertise with human resource tools to help business owners manage and operate their businesses more effectively. The company has two categories of services: Professional Employer Services (PEO) and Staffing. The majority of revenue is derived from the Professional Employer Services segment, which provides clients with human resource advisory services, HRIS access, retirement plans, a learning management system, and a web-based technology platform, myBBSI.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.